← Leaderboards
Jennifer Susan Thalappillil
State University New York Stony Brook
$114,121
Attributed
$114,121
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $42K · FY2020–22$50K$37.5K$25K$12.5K$0
'20
'21
'22
Funding mix
By agency
NIH$114,121 · 1
By mechanism
F31$114,121 · 1
Top collaborators
No co-investigators on record.
Most similar at State University New York Stony Brook
Same institution · by research overlap
- Howard C Crawford$9,133,680
- Richard Z Lin$6,856,807
- Ki Oh$185,526
- Agnieszka Beata Bialkowska$1,423,624
- Donghui Zhu$8,908,720
Others in their field
Other Emerging Leaders on “Affect”
- Chanza Baytop · Westat, Inc.$271,217,917
- Leonard Freedman · Leidos Biomedical Research, Inc.$62,378,387
- Jennifer Marie Suga · Kaiser Foundation Research Institute$29,218,159
- Lynn Briscoe · Leidos Biomedical Research, Inc.$27,788,199
- George Robert Painter · University Of Alabama At Birmingham$27,619,145
- Jessica Brooke Langbaum · Banner Health$22,633,312
Research focus
AffectBaseBiologyBone MarrowCancer CellCancer EtiologyCancer SubtypesCancer SurvivorCell Culture TechniquesCellsCell TypeCessation Of LifeCharacteristicsClustered Regularly Interspaced Short Palindromic RepeatsCoculture TechniquesConditional KnockoutCytokineDesmoplasticDiagnosisDiphtheria ToxinDisease ProgressionDs-DnaEffective Therapy3-Dimensional
Grant awards (4)
Elucidating fibroblast/immune crosstalk and plasticity in pancreatic ductal adenocarcinoma$39,523
F31 · FY2022 · CA · contact PI
Elucidating fibroblast/immune crosstalk and plasticity in pancreatic ductal adenocarcinoma$2,500
F31 · FY2022 · CA · contact PI
Elucidating fibroblast/immune crosstalk and plasticity in pancreatic ductal adenocarcinoma$36,307
F31 · FY2021 · CA · contact PI
Elucidating fibroblast/immune crosstalk and plasticity in pancreatic ductal adenocarcinoma$35,791
F31 · FY2020 · CA · contact PI